A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to trifluridine/tipiracil single agent with a Safety Lead-In part in participants with KRAS/NRAS and BRAF wild type metastatic colorectal cancer previously treated with standard treatment and anti-EGFR therapy
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Tipiracil/trifluridine (Primary) ; Fluorouracil; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms COLSTAR
Most Recent Events
- 15 Nov 2023 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 13 Sep 2023 Status changed from recruiting to discontinued.
- 29 Aug 2023 This trial has been completed in Poland (End Date: 21 Jun 2023), according to European Clinical Trials Database record.